StreetAlpha.app
Home › Stocks › ELOX

Eloxx Pharmaceuticals, Inc. (ELOX)

$10.69
▲ +0.38%
LAST CLOSE · NOV 20

Eloxx Pharmaceuticals develops drug candidates for rare genetic kidney and dermatologic diseases. It last closed at $10.69 on Nov 20, up 0.38% on the day. The next earnings report for ELOX is expected around Mon, Feb 15, 2027. For the quarter ended Sep 2026, ELOX reported EPS of -$0.49. Over its last 8 reports the stock moved an average of 9.2% the session after earnings.

AI Auto Pilots
Is ELOX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ELOX.

Key Stats

Fiscal 2025
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$6.0M
EPS (diluted)
−$0.49
Valuation
Market cap
$43.7M
4.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$56.3M
At Sep 30
Debt
$1.0M
At Dec 31
Shareholder equity
$41.1M
Shares outstanding
4.1M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $6.4M$6.4MFY2024FY2025: $0$0FY2025

From ELOX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 16).

Next report
Feb 15
Estimated date · Time not announced
Reported EPS
-$0.49
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How ELOX moved after its last 8 reports
Average move the session after a report ±9.2%
Nov 16, 2026Time not announced−3.0%
Aug 11, 2026After the close−4.8%
May 15, 2023After the close−23.7%
Apr 3, 2023Time not announced+4.0%
Nov 14, 2022After the close+8.5%
Aug 15, 2022After the close+17.1%
May 10, 2022After the close−11.4%
Apr 4, 2022Time not announced−1.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ELOXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ELOX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ELOX

Technical Analysis

ELOX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 18% below its 20 day and 31% below its 50 day average. It is 208% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot at $10.51, and the nearest resistance the Pivot R1 at $11.12.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 11.1%/day
Key levels
$119.9052 week high+1021.6%
$32.88200 day average+207.6%
$14.66100 day average+37.1%
$14.0250 day average+31.2%
$13.64Swing high (Nov 9)+27.6%
$12.5920 day average+17.8%
$11.12Pivot R1+4.0%
$10.69Last close
$10.51Pivot−1.7%
$10.51Swing low (Jul 9)−1.7%
$10.08Pivot S1−5.7%
$8.2052 week low−23.3%
Indicators
RSI (14)32.56Weak, oversold below 30Neutral
MACD-0.77Below its signal lineBearish
Stochastic14.8Near the bottom of its rangeOversold
ADX (14)42.1Strong downtrend
Williams %R-79.5Oversold below −80, overbought above −20Neutral
CCI (20)-221.2Oversold below −100, overbought above 100Oversold
Rate of change−14.1%Change over 10 sessionsBearish
ATR (14)$1.18Typical daily range, 11.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ELOX

What happened before

See how ELOX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ELOX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ELOX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ELOXHow many large options trades hit ELOX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ELOX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼6 buying vs 7 selling
  • ▼Held by funds -4.9 pts
  • ▼Funds holding -2
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2022−9.1%
In funds' top 10110.0%
Held by funds66.1%71.0%−4.9 pts
New / increased3 / 322 / 0−72.7%
Reduced / sold out2 / 50 / 0–
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ELOX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELOX is in one of them and how their past ELOX trades turned out.

ELOX in the AI portfolios
Loading…

ELOX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ELOX in an article yet. Here's the latest on the wider market.

ELOX in the news

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals is a drug development company based in Arlington, Massachusetts. It is developing product candidates for rare genetic kidney and dermatologic diseases, with an approach that targets processes such as fibrosis, inflammation and proteinuria. Its candidates are still in development. If approved, they would be prescribed to patients by physicians.

Headquarters
Arlington, MA